---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011842"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:20:35.906886+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INVO Fertility Q1 2025 revenue up 4% but net loss widens to $17.4M on $14.6M impairment

## Summary
- Revenue $1.64M, +4% YoY; clinic revenue from consolidated centers +5% to $1.62M.
- Net loss of $17.4M vs $1.6M; includes $14.6M non-cash impairment on NAYA Therapeutics assets.
- Adjusted EBITDA loss widened to $(606,551) from $(427,467) in prior year.
- Company refocuses on fertility after April 2025 decision to divest majority stake in NAYA TX.
- CEO cites supportive policy shifts and aims for cash flow break-even through clinic expansion.

## SEC filing metadata
- accession: 0001641172-25-011842
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000164117225011842/0001641172-25-011842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000164117225011842/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011842
- JSON: https://secwatch.observer/filing/0001641172-25-011842.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.